Benign prostatic hyperplasia without lower urinary tract symptoms
Methodology & AI Transparency ⓘ
Benign prostatic hyperplasia without lower urinary tract symptoms Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Benign prostatic hyperplasia without lower urinary tract symptoms is an ICD-10-CM indexed diagnosis (N40.0) within Prostate (BPH), Bladder & Urinary Tract.
- 2 Real-world patient consensus: Federal ICD-10-CM code N40.0 categorizes Benign prostatic hyperplasia without lower urinary tract symptoms under Prostate (BPH), Bladder & Urinary Tract.
- 3 Typical cash cost range: Differential triage of Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0) utilizes alpha-1 blockers [Benign prostatic hyperplasia without lower urinary tract symptoms N40.0].
- 4 Top reported side effects / signs: Longitudinal Benign prostatic hyperplasia without lower urinary tract symptoms monitoring tracks Total PSA & in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Serum Creatinine/eGFR) toward Age-specific PSA; eGFR > 75 mL/min (N40.0).
Ask our AI Specialists anything about Benign prostatic hyperplasia without lower urinary tract symptoms
What Is Benign prostatic hyperplasia without lower urinary tract symptoms?
Benign prostatic hyperplasia without lower urinary tract symptoms is an ICD-10-CM indexed diagnosis (N40.0) within Prostate (BPH), Bladder & Urinary Tract. Clinical evaluation centers on alpha-1 blockers [Benign prostatic hyperplasia without lower urinary tract symptoms N40.0] alongside serial Total PSA & in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Serum Creatinine/eGFR) tracking (Age-specific PSA; eGFR > 75 mL/min (N40.0)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
In Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0), physiological disruption stems from alpha-1A adrenergic smooth-muscle in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: tone narrowing the), informing Prostate (BPH), Bladder & Urinary Tract protocols that track IPSS Urinary Symptom in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Score) (0 – 7 (mild symptoms) (N40.0)).
Common Symptoms & Clinical Signs
- • Presentation of Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0): weak, hesitant, or in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: intermittent urinary stream)
- • Secondary Benign prostatic hyperplasia without lower urinary tract symptoms clinical sign: waking two or in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: more times nightly)
- • Symptom flares in Benign prostatic hyperplasia without lower urinary tract symptoms correlating with Total PSA & in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Serum Creatinine/eGFR) deviation outside Age-specific PSA; eGFR > 75 mL/min (N40.0)
- • Functional urology & prostate impact requiring alpha-1 blockers [Benign prostatic hyperplasia without lower urinary tract symptoms N40.0] evaluation (N40.0)
Benign prostatic hyperplasia without lower urinary tract symptoms Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N40.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NLM Clinical Tables |
| Diagnostic / Lab Marker: Total PSA & in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Score) | 0 – 7 (mild symptoms) (N40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Benign prostatic hyperplasia without lower urinary tract symptoms (N40.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N40.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Benign prostatic hyperplasia without lower urinary tract symptoms
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Terazosin Hydrochloride Hytrin • RxCUI 260376 | alpha-Adrenergic Blocker | 78% | $0.1246 | $ 7.45 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Benign prostatic hyperplasia without lower urinary tract symptoms)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Benefits and safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to: What a 1,144-Participant Study Found However, therapy discontinuation due to pain and AEs did not increase with increase in AEs. American journal of men's health • 2020-01-15 • Meta-Analysis | N = 1,144 | 94/100 | PMID 33342335 ↗ |
| New Insights on Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating: What a 1,531-Participant Study Found Tadalafil combined with tamsulosin was more effective in the treatment of male LUTS/BPH, with or without ED, on the improvement of total IPSS, QoL, and Qmax. Urologia internationalis • 2024-01-15 • Meta-Analysis | N = 1,531 | 94/100 | PMID 38081154 ↗ |
| New Insights on Tadalafil on nighttime voiding (nocturia) in men with lower urinary tract: What a 752-Participant Study Found A statistically significant improvement in nocturnal frequency was seen with tadalafil over placebo; however, the treatment difference was small and not considered clinically meaningful. World journal of urology • 2014-10-15 • Randomized Controlled Trial | N = 752 | 93/100 | PMID 24504761 ↗ |
| New Insights on Heart and blood vessel risk factors and related comorbid conditions and medical: What a 746-Participant Study Found Once-daily tadalafil 5 mg improved LUTS/BPH, regardless of severity, in men with coexisting heart and blood vessel risk factors/comorbidities, except for patients with history of > 1 drug for arterial high blood pressure. International journal of clinical practice • 2015-12-15 • Randomized Controlled Trial | N = 746 | 93/100 | PMID 26299520 ↗ |
Benign prostatic hyperplasia without lower urinary tract symptoms Patient Community & “People Like Me” Threads
Filter Benign prostatic hyperplasia without lower urinary tract symptoms community threads and patient logs by age, biological sex, dosage, and treatment duration.